Osteopore secures market approvals in Singapore and Vietnam

Osteopore Limited (ASX: $OSX) has obtained regulatory clearance from Singapore's Health Sciences Authority (HSA) and Vietnam's Department of Medical Equipment and Construction (DMEC) for its groundbreaking orthopaedic products, including a suite of off-the-shelf and customisable implants. The approvals validate Osteopore's positioning in the high-growth global orthopaedic market, particularly in the Singaporean and Vietnamese markets.

Executive Commentary on Market Expansion

We are delighted to share another positive step in the ongoing transformation of the Company. The orthopaedic market is a high-value and high-volume segment with the HTO market expected to grow at a CAGR of 9.2%. These approvals enable Osteopore to supply off-the-shelf and customisable implants, positioning us to capture the potential of these high growth market segments.

Summary of Market Approvals and Outlook

Osteopore Limited (ASX: $OSX) has successfully secured market approvals in Singapore and Vietnam for its orthopaedic products, paving the way for high-value complex bone reconstruction procedures and general bone grafting procedures. With the HTO market expected to grow at a CAGR of 9.2% and the general bone grafting market projected to expand at a CAGR of 2.3%, Osteopore is well-positioned to capitalize on the potential of these high-growth market segments. The Company's focus on Singapore and Vietnam, two of its highest performing countries, demonstrates its strategic approach to leveraging existing sales and distribution channels for accelerated market access while managing associated costs. The projected robust growth in Vietnam's orthopaedic market further enhances Osteopore's outlook. Looking ahead, Osteopore aims to launch its orthopaedic products in these markets, presenting a significant market opportunity of approximately 400,000 procedures in the Asia Pacific region annually by 2025, subject to product availability.